Application of chimeric mice with humanized liver for predictive ADME

被引:44
作者
Katoh, Miki [1 ]
Yokoi, Tsuyoshi [1 ]
机构
[1] Kanazawa Univ, Grad Sch Med Sci, Div Pharmaceut Sci, Kanazawa, Ishikawa 9201192, Japan
关键词
chimeric mice with humanized liver; drug metabolism; cytochrome P450; phase II enzyme; enzyme induction; enzyme inhibition; pharmacokinetics; excretion;
D O I
10.1080/03602530601021340
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Much effort to extrapolate the in vivo phammacokinetics of drugs in human from experimental animals or in vitro studies has been made by many researchers. A urokinase-type plasminogen activator(+/+)/severe combined immunodeficient transgenic mouse line, in which the liver could be replaced by more than 80% with human hepatocytes, was established recently in Japan. This chimeric mouse line is remarkable because the replacement is higher than any other chimeric mouse reported previously. Since the liver is the critical organ involved in the pharmacokinetics of drugs, human liver is essential for the development of new drugs. To predict the human drug metabolism and pharmacokinetics, human hepatocytes and liver microsomes are recognized as better tools and are frequently used. Thus, chimeric mice with humanized liver would have great advantages in studies on drug metabolism and pharmacokinetics. We have evaluated chimeric mice for studies on absorption, distribution, metabolism, and excretion (ADME). In the liver of the chimeric mice, human phase I and phase H enzymes were clarified to be expressed and to have a similar drug metabolizing capacity as the donor. Human specific metabolites could be detected in the serum, suggesting that the chimeric mice might be used as a human ADME model for both in vitro and in vivo studies. For predicting human drug interactions, enzyme induction and inhibition are serious problems. By the treatment with typical inducers, human CYP1A2 and CYP3A4 expressed in the liver of the chimeric mice had induction potencies. After the treatment with quinidine, a specific inhibitor of human CYP2D6, the area under the curve (AUC) of a CYP2D6 metabolite, 4'-hydroxydebrisoquin, was significantly decreased in the chimeric mice but not in the control mice. Therefore, it was indicated that the chimeric mice could be used for assessing the drug interactions via enzyme induction and inhibition. As well as drug metabolism, the drug excretion was demonstrated to be humanized because cefmetazole was mainly excreted in urine both in the chimeric mice and human but in feces in control uPA(-/-)/SCID mice. In this review, basic researches on ADME in the chimeric mice with humanized liver are summarized and the application of the chimeric mice for predictive ADME is proposed.
引用
收藏
页码:145 / 157
页数:13
相关论文
共 45 条
[1]   Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: Pitfalls, progress and promise [J].
Bachmann, KA .
CURRENT DRUG METABOLISM, 2006, 7 (01) :1-14
[2]   CLINICAL IMPLICATIONS OF THE COMPETITIVE-INHIBITION OF THE DEBRISOQUIN-METABOLIZING ISOZYME BY QUINIDINE [J].
CAPORASO, NE ;
SHAW, GL .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (10) :1985-1992
[3]   The CYP2D6 humanized mouse:: Effect of the human CYP2D6 transgene and HNF4α on the disposition of debrisoquine in the mouse [J].
Corchero, J ;
Granvil, CP ;
Akiyama, TE ;
Hayhurst, GP ;
Pimprale, S ;
Feigenbaum, L ;
Idle, JR ;
Gonzalez, FJ .
MOLECULAR PHARMACOLOGY, 2001, 60 (06) :1260-1267
[4]   Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus [J].
Dandri, M ;
Burda, MR ;
Török, E ;
Pollok, JM ;
Iwanska, A ;
Sommer, G ;
Rogiers, X ;
Rogler, CE ;
Gupta, S ;
Will, H ;
Greten, H ;
Petersen, J .
HEPATOLOGY, 2001, 33 (04) :981-988
[5]   Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition [J].
Dresser, GK ;
Spence, JD ;
Bailey, DG .
CLINICAL PHARMACOKINETICS, 2000, 38 (01) :41-57
[6]   Pharmacogenomics and individualized drug therapy [J].
Eichelbaum, M ;
Ingelman-Sundberg, M ;
Evans, WE .
ANNUAL REVIEW OF MEDICINE, 2006, 57 :119-137
[7]   Effect of multiple doses of rifampin on the [14C N-methyl] erythromycin breath test in healthy male volunteers [J].
Gharaibeh, MN ;
Gillen, LP ;
Osborne, B ;
Schwartz, JI ;
Waldman, SA .
JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (06) :492-495
[8]   Human hepatocytes as a tool for studying toxicity and drug metabolism [J].
Gómez-Lechón, MJ ;
Donato, MT ;
Castell, JV ;
Jover, R .
CURRENT DRUG METABOLISM, 2003, 4 (04) :292-312
[9]   Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update [J].
Hemeryck, A ;
Belpaire, FM .
CURRENT DRUG METABOLISM, 2002, 3 (01) :13-37
[10]   Catalytic specificity of CYP2D isoforms in rat and human [J].
Hiroi, T ;
Chow, T ;
Imaoka, S ;
Funae, Y .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (09) :970-976